UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
18.59
-1.42 (-7.10%)
Aug 7, 2025, 4:00 PM - Market closed
SolarWinds Employees
UroGen Pharma had 235 employees as of December 31, 2024. The number of employees increased by 34 or 16.92% compared to the previous year.
Employees
235
Change (1Y)
34
Growth (1Y)
16.92%
Revenue / Employee
$401,013
Profits / Employee
-$659,438
Market Cap
858.88M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 235 | 34 | 16.92% |
| Dec 31, 2023 | 201 | 1 | 0.50% |
| Dec 31, 2022 | 200 | 5 | 2.56% |
| Dec 31, 2021 | 195 | 8 | 4.28% |
| Dec 31, 2020 | 187 | 14 | 8.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
URGN News
- 1 day ago - UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 3 days ago - UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - GlobeNewsWire
- 10 days ago - UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025 - GlobeNewsWire
- 11 days ago - UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology - GlobeNewsWire
- 18 days ago - UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - GlobeNewsWire
- 4 weeks ago - UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - GlobeNewsWire
- 7 weeks ago - URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 28 Court Deadline (NASDAQ:URGN) - GlobeNewsWire
- 7 weeks ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen - PRNewsWire